TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT06157177: Efficacy of M640 in Acute Lumbosacral Musculoskeletal Conditions.

Sponsor: Primus Pharmaceuticals · Phase: PHASE4 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 50 pts

Competing Trials Overlap

14 Active Trials

Excess Burn Exposure

$2,045,120

Rescue Site Savings

+$1,354,560

Unlock Full NCT06157177 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06157177 Rescue Dossier →